Edition:
United States

Immutep Ltd (IMMP.OQ)

IMMP.OQ on NASDAQ Stock Exchange Global Market

2.32USD
21 Jun 2018
Change (% chg)

-- (--)
Prev Close
$2.32
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
12,008
52-wk High
$3.06
52-wk Low
$1.25

Latest Key Developments (Source: Significant Developments)

Immutep Announces United States Patent Grant For IMP701 Antibody
Monday, 5 Mar 2018 04:21pm EST 

March 6 (Reuters) - Immutep Ltd ::ANNOUNCES UNITED STATES PATENT GRANT FOR IMP701 ANTIBODY.  Full Article

Immutep Says ‍H1 Net Loss Attributable $4.3 Million
Thursday, 22 Feb 2018 01:35am EST 

Feb 22 (Reuters) - Immutep Ltd ::H1 REVENUE $2.6 MILLION .‍H1 NET LOSS ATTRIBUTABLE $4.3 MILLION VERSUS LOSS OF $4.1 MILLION A YEAR AGO​.  Full Article

Prima Biomed says Lucy Turnbull steps down as chairman​
Thursday, 16 Nov 2017 04:24pm EST 

Nov 17 (Reuters) - Prima Biomed Ltd ::Russell Howard appointed as chairman​.Lucy Turnbull steps down as chairman​.‍vice-Chairman Albert Wong to step down​.  Full Article

Prima Biomed files for offer and sale of up to 197.35 mln ordinary shares
Thursday, 19 Oct 2017 04:54pm EDT 

Oct 20 (Reuters) - Prima Biomed Ltd :Prima Biomed Ltd files for offer and sale of up to 197.35 million ordinary shares, represented by 1.97 million adss‍​ by selling shareholders - SEC filing.  Full Article

Prima Biomed Prima secures Japanese patent grant for IMP731 antibody
Thursday, 7 Sep 2017 10:58pm EDT 

Sept 8 (Reuters) - Prima Biomed Ltd ::Prima secures Japanese patent grant for imp731 antibody.  Full Article

Prima Biomed enters securities purchase agreement to purchase 2.6 mln of its American Depositary shares
Thursday, 29 Jun 2017 07:28pm EDT 

June 30 (Reuters) - Prima Biomed Ltd :Entered into a securities purchase agreement with certain accredited investors to purchase 2.6 million of its american depositary shares.Total gross proceeds of approximately us$5.0 million.To purchase its american depositary shares at a purchase price of us$1.90 per ads in a registered direct offering.Prima intends to use net proceeds from this offering to continue ongoing clinical development of imp321.  Full Article

Prima Biomed announces pricing of direct offering of its American Depositary Shares
Thursday, 29 Jun 2017 11:34am EDT 

June 29 (Reuters) - Prima Biomed Ltd :Prima Biomed Ltd announces pricing of $5.0 million registered direct offering of its American depositary shares.Prima Biomed - Entered into a securities purchase agreement with certain accredited investors to purchase 2.6 million of its American depositary shares at $1.90 per ADS.Prima Biomed - In a concurrent private placement, co agreed to issue unregistered warrants to purchase up to 1,973,451 of its ADS.Prima Biomed - The warrants have an exercise price of $2.50 per ADS, are exercisable immediately and will expire 5.5 years from the date of issuance.  Full Article

Prima Biomed says approval has been granted for third cohort of its phase i clinical trial for IMP321 in combination with KEYTRUDA
Tuesday, 18 Apr 2017 09:40pm EDT 

April 19 (Reuters) - Prima Biomed Ltd -:Asx alert-approval received to commence 3rd cohort of melanoma trial-prr.ax.Approval has been granted for third cohort of its phase i clinical trial for imp321 in combination with keytruda.  Full Article

Prima BioMed announces data from IMP321 AIPAC clinical trial in breast cancer
Wednesday, 21 Dec 2016 04:33pm EST 

Prima BioMed Ltd : Prima BioMed Ltd - data demonstrated activation and an increased level of blood monocytes, dendritic cells and CD8 T-cells . Prima BioMed Ltd - IMP321 is safe and well tolerated . Prima BioMed Ltd - subject to confirmation of dose escalation committee on 30 Dec, Prima will now commence randomised phase of trial in January 2017 . Prima BioMed Ltd - patients will receive paclitaxel treatment plus placebo or paclitaxel in conjunction with imp321 .Prima BioMed announces data from IMP321 AIPAC clinical trial in breast cancer.  Full Article

Prima signs MOU with WuXi
Tuesday, 22 Nov 2016 08:15pm EST 

Prima Biomed Ltd - : WuXi & Prima sign MOU for strategic partnership .Mou was signed to form a strategic biologics development and manufacturing partnership.  Full Article